GlassScriptPhysician profile
Danielle M Zachar
NPI 1639602832
$6,581.01
in general payments reported to CMS, 2019-2025
31 companies · $1,816 in 2025
The $1,816 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $231 · 2021: $334 · 2022: $769 · 2023: $1,252 · 2024: $1,687 · 2025: $1,816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,680 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,679.58 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,330.29 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $942.87 | 2020-2025 | |
| Novo Nordisk INC | $822.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $685.73 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $669.69 | 2020-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Astellas Pharma US INC | $353.51 | 2022-2025 | Veozah, Myrbetriq |
| Amgen INC. | $290.72 | 2023-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $245.29 | 2022-2025 | Vraylar, Ubrelvy |
| Exact Sciences Corporation | $169.72 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $135.44 | 2019-2020 | |
| Abbott Laboratories | $117.66 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| E.R. Squibb & Sons, L.L.C. | $104.50 | 2022-2025 | Eliquis, Camzyos |
| Phathom Pharmaceuticals, INC. | $89.37 | 2023-2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $88.71 | 2022 | |
| Shield Therapeutics INC | $73.23 | 2023-2024 | Accrufer |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $61.64 | 2025 | Zenpep |
| Bayer Healthcare Pharmaceuticals INC. | $49.39 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $43.59 | 2023-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $41.41 | 2022-2023 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Tonix Medicines, INC. | $40.28 | 2025 | Tonmya |
| Edwards Lifesciences Corporation | $37.81 | 2020-2021 | |
| Dexcom, INC. | $28.54 | 2021-2022 | |
| Insulet Corporation | $21.51 | 2024 | Omnipod |
| Teva Pharmaceuticals USA, INC. | $20.56 | 2025 | Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.01 | 2023 | Spiriva Respimat |
| Millicent US INC | $18.18 | 2025 | Femlyv, Intrarosa |
| Xeris Pharmaceuticals, INC. | $17.07 | 2025 | Gvoke Hypopen |
| Eisai INC. | $16.39 | 2024 | |
| Sanofi Pasteur INC. | $15.80 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.19 | 2023 | Xifaxan, Trulance |
| Boston Scientific Corporation | $14.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Zachar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.